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Abstract
Acute kidney injury (AKI) is independently associated with increased morbidity and mortality. Ischemia is the
leading cause of AKI, and short of supportive measures, no currently available therapy can effectively treat or
prevent ischemic AKI. This paper discusses recent developments in the understanding of ischemic AKI
pathophysiology, the emerging relationship between ischemic AKI and development of progressive chronic kidney
disease, and promising novel therapies currently under investigation. On the basis of recent breakthroughs in
understanding the pathophysiology of ischemic AKI, therapies that can treat or even prevent ischemic AKI may
become a reality in the near future.
Introduction
Acute kidney injury (AKI) is independently associated
with increased morbidity and mortality. AKI has been
associated with increased length of hospital stay and
adjusted odds ratios of 4.1 for hospital mortality and 2.0
for discharge to short- and long-term care facilities [1].
Among critically ill patients, period prevalence of AKI
in a multinational, multicenter study comprising
approximately 30,000 patients was demonstrated to be
5.7%. The major contributing factors were shock (septic
shock 47.5%), major surgery and hypovolemia. Observed
mortality in this study was 60.3% compared with the
predicted mortality of 45.6% using the simplified acute
physiology score II [2]. Short of supportive measures, no
available therapy has definitively proven to effectively
treat or prevent ischemic AKI. Recent experimental
research has helped elucidate the pathophysiologic basis
behind ischemic AKI, and therapies that can treat or
even prevent ischemic AKI may become a reality in the
near future. This paper discusses recent developments
in the understanding of ischemic AKI pathophysiology,
the emerging relationship between ischemic AKI and
the development of progressive chronic kidney disease
(CKD), and promising novel therapies currently under
investigation.
Pathobiology of ischemia
While the human adult kidneys account for 2% of total
body weight, they receive approximately 25% of the car-
diac output. This facilitates the high rates of glomerular
filtration required for the precise regulation of the
body’s fluid and electrolyte balance. With autoregula-
tion, glomerular filtration rate (GFR) is tightly main-
tained despite changes in arteriolar pressure; GFR
remains constant while systemic blood pressure fluctu-
ates between 80 and 180 mmHg (Figure 1) [3]. Under
physiologic conditions, the renal cortex, which contains
the majority of the glomeruli (or filtering units), receives
most of the renal blood flow, whereas the medulla
receives approximately 10% [4]. During ischemia, the
reduction in blood flow is regional rather than uniform
throughout the kidney. The decrease in renal blood flow
is more prominent in the outer medulla than in the cor-
tex [5]. The source of medullary blood flow arises from
the efferent arterioles of the juxtamedullary glomeruli
giving rise to the vasa recta. This serially organized
renal microvasculature allows for the countercurrent
mechanisms vital for sodium balance. Tubular transport
in the medullary thick ascending limb (TAL) and S3
segment of the proximal tubule demands high oxygen
consumption. If the blood supply becomes interrupted
transiently, the oxygen balance is maintained by redu-
cing GFR and solute transport to the TAL. This protec-
tive mechanism is undermined by production of reactive
oxygen species that further decrease medullary blood
flow and increase TAL activity. Clinically, this translates
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the oxygen balance is tilted toward consumption
because of increased demand for tubular transport. As
discussed below, the initial injury further initiates a cas-
cade of events leading to endothelial damage. An
inflammatory response also leads to vascular congestion
that propagates the hypoxic environment and reduces
the ability to clear the toxic radicals. Thus the cortico-
medullary region is the most vulnerable region of the
kidney to tubular injury, inflammation and vascular
alterations that extend the cellular injury beyond the
initial insult and propagate continued hypoperfusion [6].
Observed vascular alterations include disruption of the
endothelial actin cytoskeleton, leading to the detach-
ment of cells from the endothelial monolayer.
This results in altered endothelial barrier function, vas-
cular reactivity and increased permeability [6,7]. The
inflammatory response leads to enhanced leukocyte-
endothelium interactions, leading to increased expression
of intercellular adhesion molecules (ICAM) such as
ICAM-1, P- and E-selectin and B7-1. Experiments that
ablate or decrease the expression of these molecules
a t t e n u a t ek i d n e yi n j u r ya n dp r e s e r v ek i d n e yf u n c t i o ni n
animal models of ischemic and septic AKI [6]. The leuko-
cyte-endothelium interaction also leads to shedding of
the sulfated glycosaminoglycan-rich layer, or glycocalyx,
of the endothelium. This subsequently initiates down-
stream signaling cascades and increases access of leuko-
cytes to transmigrate the endothelium into the injured
kidney [8]. These factors collectively create an environ-
ment that leads to further tubular injury and propagates
the initial insult, resulting in a further decrease in GFR
and kidney function (Figure 2).
Progression to chronic kidney disease
Clinical episodes of AKI may have lasting implications,
and new data suggest that these include increasing the
likelihood of subsequent development of CKD [9-12].
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Figure 1 Renal vascular autoregulation involves three mechanisms: the myogenic reflex (MR), tubuloglomerular feedback (TGF) and a
recently discovered third regulatory mechanism (3M). MR refers to the contraction of the smooth muscle in response to stretching forces.
TGF is a kidney-specific regulatory mechanism that causes vasoconstriction of the afferent arterioles in response to increased luminal
concentration of chloride at the macula densa in the early distal tubule. 3 M takes place chronologically after MR and TGF and was discovered
when it was observed that renovascular autoregulation took place well after MR took place and after TGF was inhibited by furosemide
administration. (A) Increase in pressure leads to passive stretch. (B) Regulatory mechanisms are activated to maintain renal blood flow via
smooth muscle contraction of afferent and efferent arterioles. (C) Three regulatory mechanisms work in concert. MR occurs early and is
completed in 10 seconds. TGF and 3 M are late responses, with a delay of 10 to 15 seconds, and take 30 to 60 seconds to complete. (D)
Autoregulation maintains constant renal blood flow and glomerular flow rate while systemic blood pressure fluctuates between 80 and 180
mmHg.
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et al. [13] more than a decade ago on the basis of renal
biopsy findings in patients with CKD that demonstrated
marked rarefaction of the peritubular capillaries [12].
Their hypothesis proposed that primary glomerular
injury leads to reduced postglomerular flow, which cul-
minates in peritubular capillary loss [13]. This creates a
hypoxic environment that produces a fibrotic response
that further propagates injury by affecting adjacent unaf-
fected capillaries. Another perspective is that renal
injury triggers an inflammatory response that recruits
profibrotic cytokines such as transforming growth factor
1 and further induces the transformation of renal
epithelial and endothelial cells to myofibroblasts, a pro-
cess called epithelial mesenchymal transition [14]. This
leads to fibroblast and myofibroblast production in the
matrix, with subsequent tubulointerstitial injury and
atrophy [11]. The histopathological hallmark of CKD is
tubulointerstitial fibrosis,a n dt h ed e g r e eo ff i b r o s i si s
the best predictor for the progression to end-stage renal
disease [10].
In addition to profibrotic processes, hypoxia also sup-
presses matrix degradation via reduced expression and
activity of matrix metalloproteinases such as collagen
metalloproteinase-I [15]. Fibrosis itself is not sufficient
to impede the function of the kidney. The eventual loss
of the microvasculature creates a hypoxic milieu and
produces the progressive nature of fibrosis. Rarefaction
of peritubular capillaries was observed during detailed
examination of biopsies from patients with CKD [16]
and in animal models [17]. In the animal models, there
was a direct relationship between peritubular capillary
rarefaction and the development of glomerular and
tubulointerstitial scarring. Further studies in rats showed
that there was a permanent reduction in peritubular
capillary density after recovery from ischemic AKI, sug-
gesting that the acute ischemic insult leads to a chronic
hypoxic state [18].
Studies using pimonidazole, which binds to hypoxic
cells in vivo, demonstrated hypoxia of the kidney in asso-
ciation with reduction in the peritubular capillary blood
flow at an early stage of a model of progressive glomeru-
lonephritis induced by uninephrectomy and repeated
injection of antimesangial Thy1 antibody [19]. Pimonida-
zole staining also showed the existence of renal hypoxia
in polycystic kidney disease and diabetic nephropathy.
Hypoxia has also been observed in puromycin-induced
n e p h r i t i cs y n d r o m e ,a g i n gk i d n e ya n dt h er e m n a n t
A. B.
Figure 2 Peritubular capillary schematic under two conditions. (A) Cross-section of normal peritubular capillaries with an intact endothelial
monolayer anchored by the actin cytoskeleton and covered with the glycocalyx. (B) Endothelial alterations due to acute kidney injury, such as
glycocalyx disruption, actin cytoskeleton disruption, detachment of the endothelial monolayer with increased endothelium-leukocyte interaction
and expression of intracellular adhesion molecules.
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the reduction in the density of peritubular capillaries
leads to a hypoxic environment and suggest a mechanism
for the observed progression from AKI to CKD to a final
common pathway to end-stage kidney disease [20].
Hypoxia-inducible factor
A hypoxic environment increases the transcription of
genes involved in angiogenesis, erythropoiesis and anae-
robic energy metabolism. Hypoxia-inducible factor (HIF)
is thought to play a major role in this process [21]. HIF
is a basic helix-loop-helix transcription factor composed
of a-a n db-subunits. In normoxia, the a-subunit is
degraded by proteasomal degradation via proline hydro-
xylation by HIF-specific prolylhydroxylases (PHDs),
which leads to binding of von Hippel-Lindau protein
and targeted degradation through the ubiquitin-proteo-
some pathway. In hypoxic conditions, the HIF-1a subu-
nit escapes degradation, translocates to the nucleus,
forms a heterodimer with HIF-1b and binds to the
hypoxia-responsive element motif. This leads to
increased activation of between 100 and 200 genes
involved in angiogenesis, erythropoiesis and energy
metabolism [22].
Currently, there is an intense research focus on the
stabilization of HIF as a novel therapeutic option for
renal hypoxic injury, including ischemic reperfusion
injury and CKD. In an animal model of renal mass
reduction, Song et al. [23] showed that activation of HIF
by dimethyloxalylglycine attenuated the increase in pro-
teinuria and structural damage by preventing podocyte
injury. The renoprotection was accompanied by a reduc-
tion of oxidative stress, inflammation and fibrosis. Sev-
eral other experimental studies demonstrated protection
against ischemia-reperfusion (I/R) injury by stabilization
of HIF through carbon monoxide, cobalt chloride
administration, xenon anesthesia and PHD inhibitors
(PHD-I) [19,24,25]. Bernhardt et al. [26] showed
improved short- and long-term outcomes in rats that
underwent allogenic kidney transplant and were pre-
treated with PHD-I. Human studies have also been per-
formed using PHD-I as a novel treatment for anemia
through the induction of erythropoietin expression [27].
There are conflicting data regarding whether HIF pro-
motes fibrosis and progression to CKD. Higgins et al.
[28,29] demonstrated in HIF-1a-knockout mice that sta-
bilization of HIF-1 leads to increased transcription of the
profibrotic gene connective tissue growth factor (Ctgf).
They further demonstrated enhanced epithelial-to-
mesenchymal transition in vitro by HIF-1a and induced
epithelial cell migration through upregulation of lysyl
oxidase genes in mice subjected to unilateral ureteral
obstruction. HIF also has a central role in tumor
stabilization.
Angiogenesis is essential for tumor survival. As cells
grow and divide, the neoplastic compartment rapidly
e x p a n d sp a s tt h ed i f f u s i o nd i s t a n c eo fo x y g e ni nt i s s u e .
As regions of the tumor become hypoxic, HIF mediates
a cellular response resulting in angiogenesis and anaero-
bic energy metabolism. In renal cell carcinoma, there is
a biallelic inactivation of the E3 ubiquitin ligase respon-
sible for targeting the HIFa subunit for degradation.
HIF-2a seems to have a greater role in renal cell carci-
noma in disease progression while HIF-1a has a greater
role in solid tumors, demonstrating that their specificity
is important for specific tumor propagation and survival.
The role of HIF in tumor propagation must be seriously
considered, and tumorigenesis must be closely moni-
tored, with regard to the development of PHD-I [30].
Ischemia reperfusion injury and preconditioning
As previously noted, ischemia is a leading cause of AKI.
Ischemia and subsequent reperfusion elicit AKI through
endothelial dysfunction, leukocyte-mediated inflamma-
tion and decreased microvascular blood flow [31]. In a
rat model of renal I/R injury, upregulation of proteins
related to kidney development occurred in a specific
spatial and temporal sequence. The initial insult was
associated with increased expression of injury and/or
apoptosis markers, followed by a regeneration phase
with upregulation of kidney mesenchymal proteins fol-
lowed by tubular markers, with endothelial marker
expression occurring throughout early and midregenera-
tion [32]. This provides insights into the mechanisms
behind ischemic AKI and recovery and suggests specific
therapeutic targets that mayb ee f f e c t i v eo n l yd u r i n ga
narrow window around an ischemic insult.
In a mouse model of I/R injury, sphingosine-1-phos-
phate (S1PR) agonists attenuated AKI indirectly by
redirecting lymphocytes away from the kidney [33,34]
and directly by acting on the proximal tubule [35]. The
selective S1PR agonist SEW2871 reduced apoptosis in
cultured mouse proximal tubule epithelial cells induced
by I/R injury. Deletion of Dicer, a key enzyme for
microRNA production, was also associated with resis-
tance to ischemic AKI in mice [36].
Although I/R injury elicits AKI, episodes of nonlethal
ischemia may protect the kidneys against future
ischemic AKI. Ischemic preconditioning (IPC) refers to
eliciting nonlethal ischemia to provide protection against
a future ischemic insult. In mice, a first episode of renal
ischemia protected against AKI after a second episode
of renal ischemia [37]. Such renal protection was found
to be mediated by Tregulatory (Treg) lymphocytes,
which inhibit neutrophil and macrophage accumulation
in the kidney, tubular necrosis and AKI [38]. Treg cell
depletion reversed this protection, and Treg cell infusion
mimicked the effect of IPC. Other pathways through
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cell survival pathways and downregulation of apoptotic
pathways [37,39].
Remote ischemic preconditioning (RIPC) refers to eli-
citing nonlethal ischemia to an organ to protect a dis-
tant organ from future injury. In adults undergoing
abdominal aortic aneurysm repair, RIPC was induced by
two cycles of intermittent cross-clamping of the com-
mon iliac artery. This was associated with a 23%
decrease in AKI (30% vs. 7%, P =0 . 0 0 9 ) ,w h i c hw a s
defined by a rise in serum creatinine to >177 μM/L
(2 mg/dL) [40]. However, in another study, in patients
undergoing multivessel coronary artery bypass graft
(CABG) surgery, the incidence of AKI in those who
received RIPC was no different than that of controls
[41]. In another study, RIPC was elicited with three
5-minute cycles of upper-extremity ischemia elicited
using a blood pressure cuff [42]. In the most recently
published retrospective study of nondiabetic adults
undergoing CABG surgery, RIPC was also elicited with
three 5-minute cycles of upper-extremity ischemia using
a blood pressure cuff. Compared with controls, fewer
patients receiving RIPC developed AKI as defined using
the Acute Kidney Injury Network definition [43]. RIPC
has been demonstrated to attenuate systemic inflamma-
tion [43,44]. Further study of IPC and RIPC in kidney
protection may not only elucidate the pathobiology of
ischemic AKI but also lead to effective AKI treatments
if indeed IPC and RIPC are renoprotective.
Conclusion
Pathophysiologic changes secondary to ischemic AKI
lead to endothelial injury with disruption of the endothe-
lial monolayer, as well as increased leukocyte endothelial
interaction and recruitment. The inflammatory process
eventually leads to rarefaction of the peritubular capil-
laries, shifting the fragile balance of oxygen supply and
demand to the corticomedullary junction toward a nega-
tive oxygen balance. The shift in balance causes a hypoxic
environment, leading to accumulation of fibrosis and
development of CKI. Factors involved in adaptation to
this hypoxic environment, such as HIF, may have poten-
tial as therapeutic targets, but their application must be
balanced against the profibrotic and tumor-producing
potential of HIF stabilizers. Moreover, further evaluation
of IPC and RIPC may not only elucidate the pathobiology
of ischemic AKI but also hold promise as effective thera-
pies in primary AKI prevention.
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